http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 15 Jul 2026 10:42:42 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Corporate+News/Ernexa%27s+ERNA-101+combo+shows+tumor+clearance+in+animal+study/26770988.html <p>Ernexa Therapeutics (Nasdaq: ERNA) announced preclinical data from an independently conducted study showing complete tumor clearance and long-term survival in two-thirds of animals treated with its lead cell therapy candidate, ERNA-101, combined with anti-PD-1 therapy in an ovarian cancer model.</p><p>The study, conducted by an independent contract research organization, used an immunocompetent ID8luc-ova syngeneic ovarian cancer model with four treatment arms. Complete tumor clearance and durable survival were observed in 10 of 15 animals receiving the combination therapy. No complete responses were recorded in animals treated with ERNA-101 alone, anti-PD-1 alone, or left untreated.</p><p>The independent study reproduced earlier findings generated at http://www.streetinsider.com/Corporate+News/Ernexa%27s+ERNA-101+combo+shows+tumor+clearance+in+animal+study/26770988.html Wed, 15 Jul 2026 07:50:45 -0400 ERNA http://www.streetinsider.com/FDA/Ernexa%27s+ERNA-101+combo+shows+tumor+clearance+in+animal+study/26770988.html <p>Ernexa Therapeutics (Nasdaq: ERNA) announced preclinical data from an independently conducted study showing complete tumor clearance and long-term survival in two-thirds of animals treated with its lead cell therapy candidate, ERNA-101, combined with anti-PD-1 therapy in an ovarian cancer model.</p><p>The study, conducted by an independent contract research organization, used an immunocompetent ID8luc-ova syngeneic ovarian cancer model with four treatment arms. Complete tumor clearance and durable survival were observed in 10 of 15 animals receiving the combination therapy. No complete responses were recorded in animals treated with ERNA-101 alone, anti-PD-1 alone, or left untreated.</p><p>The independent study reproduced earlier findings generated at http://www.streetinsider.com/FDA/Ernexa%27s+ERNA-101+combo+shows+tumor+clearance+in+animal+study/26770988.html Wed, 15 Jul 2026 07:50:45 -0400 ERNA http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Receives+Independent+Validation+of+ERNA-101+with+Complete+Tumor+Clearance+and+Durable+Survival+in+Ovarian+Cancer+Models+Ahead+of+Planned+Clinical+Entry/26770982.html <p align="center"><em>Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND </em></p> <p align="center"><em>ERNA-101 Plus Anti-PD-1 Achieved Complete Tumor Clearance and Long-Term Survival in Two-Thirds of Treated Animals While No Complete Responses Were Observed in Any Monotherapy or Control Group</em></p> <p align="center"><em>IND Submission Planned for Q3 2026 with First-in-Human Phase 1 Trial Expected to Begin in Q4 2026</em></p> <p align="justify">CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=XWJsqzzwud_qPbOSyGFEAbfsg2MnE_rI3nJfKdrkMWphMMZDrSoTxgK0PHuDqp5Ckmgs9wciAPiW8Oe6cVSFa7_XCNq0ZdGWIJ_Q1_PEtVU=" rel="nofollow" target="_blank"><u>Ernexa Therapeutics</u></a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Receives+Independent+Validation+of+ERNA-101+with+Complete+Tumor+Clearance+and+Durable+Survival+in+Ovarian+Cancer+Models+Ahead+of+Planned+Clinical+Entry/26770982.html Wed, 15 Jul 2026 07:50:00 -0400 ERNA ERNA http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Receives+Independent+Validation+of+ERNA-101+with+Complete+Tumor+Clearance+and+Durable+Survival+in+Ovarian+Cancer+Models+Ahead+of+Planned+Clinical+Entry/26770982.html <p align="center"><em>Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND </em></p> <p align="center"><em>ERNA-101 Plus Anti-PD-1 Achieved Complete Tumor Clearance and Long-Term Survival in Two-Thirds of Treated Animals While No Complete Responses Were Observed in Any Monotherapy or Control Group</em></p> <p align="center"><em>IND Submission Planned for Q3 2026 with First-in-Human Phase 1 Trial Expected to Begin in Q4 2026</em></p> <p align="justify">CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=XWJsqzzwud_qPbOSyGFEAbfsg2MnE_rI3nJfKdrkMWphMMZDrSoTxgK0PHuDqp5Ckmgs9wciAPiW8Oe6cVSFa7_XCNq0ZdGWIJ_Q1_PEtVU=" rel="nofollow" target="_blank"><u>Ernexa Therapeutics</u></a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Receives+Independent+Validation+of+ERNA-101+with+Complete+Tumor+Clearance+and+Durable+Survival+in+Ovarian+Cancer+Models+Ahead+of+Planned+Clinical+Entry/26770982.html Wed, 15 Jul 2026 07:50:00 -0400 ERNA ERNA http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Receives+Independent+Validation+of+ERNA-101+with+Complete+Tumor+Clearance+and+Durable+Survival+in+Ovarian+Cancer+Models+Ahead+of+Planned+Clinical+Entry/26770982.html <p align="center"><em>Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND </em></p> <p align="center"><em>ERNA-101 Plus Anti-PD-1 Achieved Complete Tumor Clearance and Long-Term Survival in Two-Thirds of Treated Animals While No Complete Responses Were Observed in Any Monotherapy or Control Group</em></p> <p align="center"><em>IND Submission Planned for Q3 2026 with First-in-Human Phase 1 Trial Expected to Begin in Q4 2026</em></p> <p align="justify">CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=XWJsqzzwud_qPbOSyGFEAbfsg2MnE_rI3nJfKdrkMWphMMZDrSoTxgK0PHuDqp5Ckmgs9wciAPiW8Oe6cVSFa7_XCNq0ZdGWIJ_Q1_PEtVU=" rel="nofollow" target="_blank"><u>Ernexa Therapeutics</u></a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Receives+Independent+Validation+of+ERNA-101+with+Complete+Tumor+Clearance+and+Durable+Survival+in+Ovarian+Cancer+Models+Ahead+of+Planned+Clinical+Entry/26770982.html Wed, 15 Jul 2026 07:50:00 -0400 ERNA ERNA